Patent Ductus Arteriosus: One Recommendation Does Not Fit All

neonatoloji-4-4-2023

Yasemin Ezgi KÖSTEKCİa, Ömer ERDEVEa

aAnkara University Faculty of Medicine, Department of Pediatrics, Division of Neonatology, Ankara, Türkiye

ABSTRACT
Ductus arteriosus which is a physiological necessity for intrauterine life, when is not capable of closing in the preterm infant due to the anatomical characteristics of the tissue, results in a number of hemodynamic alterations and an increase in preterm morbidity. Hemodynamically significant patent ductus arteriosus (hsPDA) is still an elusive condition that challenges neonatologists and pediatric cardiologists due to recent advances in the field of neonatology. The short- and long-term effects of hsPDA have been the focus of several research, reports, reviews, and meta-analyses. The current research questions at new era are to treat PDA or not, and if to treat who is the target patient that may benefit from the treatment. Nowadays, more interoceptive approach among NICUs is rising depending on the outcomes of recently published studies concerning expectant management. Therefore, it would be the best to make decisions about PDA management and follow-up on an individual basis, considering the balance of benefits and harms of both medical and surgical treatments. It is also essential to design scoring and prediction models to support these decisions and to identify patients who require and will benefit from treatment.
Keywords: Acetaminophen; conservative; ibuprofen; indomethacin; patent ductus arteriosus; precision medicine

Referanslar

  1. Elsayed YN, Fraser D. Patent Ductus Arteriosus in Preterm Infants, Part 1: Understanding the Pathophysiologic Link Between the Patent Ductus Arteriosus and Clinical Complications. Neonatal Netw. 2017;36:265-72. [Crossref]  [PubMed]
  2. Clyman RI, Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Hakansson S, et al. PDA-TOLERATE Trial: An Exploratory Randomized Controlled Trial of Treatment of Moderate-to-Large Patent Ductus Arteriosus at 1 Week of Age. J Pediatr. 2019;205:41-8.e46. [Crossref]  [PubMed]  [PMC]
  3. Potsiurko S, Dobryanskyy D, Sekretar L, Salabay Z. Randomized Noninferiority Trial of Expectant Management versus Early Treatment of Patent Ductus Arteriosus in Preterm Infants. Am J Perinatol. 2022. [Crossref]  [PubMed]
  4. Sung SI, Lee MH, Ahn SY, Chang YS, Park WS. Effect of Nonintervention vs Oral Ibuprofen in Patent Ductus Arteriosus in Preterm Infants: A Randomized Clinical Trial. JAMA Pediatr. 2020;174:755-63. [Crossref]  [PubMed]  [PMC]
  5. Hundscheid T, Onland W, Kooi EMW, Vijlbrief DC, de Vries WB, Dijkman KP,et al. Expectant Management or Early Ibuprofen for Patent Ductus Arteriosus. N Engl J Med. 2023;388:980-90. [Crossref]  [PubMed]
  6. Gupta S, Juszczak E, Hardy P, Subhedar N, Wyllie J, Kelsall W, et al. Study protocol: baby-OSCAR trial: Outcome after Selective early treatment for Closure of patent ductus ARteriosus in preterm babies, a multicentre, masked, randomised placebo-controlled parallel group trial. BMC Pediatr. 2021;21:100. [Crossref]
  7. Kluckow M, Lemmers P. Hemodynamic assessment of the patent ductus arteriosus: Beyond ultrasound. Semin Fetal Neonatal Med. 2018;23:239-44. [Crossref]  [PubMed]
  8. Liebowitz M, Kaempf J, Erdeve O, Bulbul A, Hakansson S, Lindqvist J, et al. Comparative effectiveness of drugs used to constrict the patent ductus arteriosus: a secondary analysis of the PDA-TOLERATE trial (NCT01958320). J Perinatol. 2019;39:599-607. [Crossref]  [PubMed]  [PMC]
  9. Clyman RI, Hills NK. Patent ductus arteriosus (PDA) and pulmonary morbidity: can early targeted pharmacologic PDA treatment decrease the risk of bronchopulmonary dysplasia? Semin Perinatol. 2023;47(2):151718. [Crossref]  [PubMed]
  10. Backes CH, Hill KD, Shelton EL, Slaughter JL, Lewis TR, Weisz DE,et al. Patent Ductus Arteriosus: A Contemporary Perspective for the Pediatric and Adult Cardiac Care Provider. J Am Heart Assoc. 2022;11:e025784. [Crossref]  [PubMed]  [PMC]
  11. Sankar MN, Bhombal S, Benitz WE. PDA: To treat or not to treat. Congenit Heart Dis. 2019;14:46-51. [Crossref]  [PubMed]
  12. Singh Y, Fraisse A, Erdeve O, Atasay B. Echocardiographic diagnosis and hemodynamic evaluation of patent ductus arteriosus in extremely low gestational age newborn (ELGAN) infants. Frontiers in Pediatrics. 2020;8:573627. [Crossref]  [PubMed]  [PMC]
  13. de Boode WP, Singh Y, Gupta S, Austin T, Bohlin K, Dempsey E, et al. Recommendations for neonatologist performed echocardiography in Europe: Consensus Statement endorsed by European Society for Paediatric Research (ESPR) and European Society for Neonatology (ESN). Pediatr Res. 2016;80:465-71. [Crossref]  [PubMed]  [PMC]
  14. de Boode WP, Kluckow M, McNamara PJ, Gupta S. Role of neonatologist-performed echocardiography in the assessment and management of patent ductus arteriosus physiology in the newborn. Semin Fetal Neonatal Med. 2018;23:292-7. [Crossref]  [PubMed]
  15. Cotton RB, Lindstrom DP, Stahlman MT. Early prediction of symptomatic patent ductus arteriosus from perinatal risk factors: a discriminant analysis model. Acta Paediatr Scand. 1981;70:723-7. [Crossref]  [PubMed]
  16. Yeh TF, Raval D, Luken J, Thalji A, Lilien L, Pildes RS. Clinical evaluation of premature infants with patent ductus arteriosus: a scoring system with echocardiogram, acid-base, and blood gas correlations. Crit Care Med. 1981;9:655-7. [Crossref]  [PubMed]
  17. Kindler A, Seipolt B, Heilmann A, Range U, Rudiger M, Hofmann SR. Development of a Diagnostic Clinical Score for Hemodynamically Significant Patent Ductus Arteriosus. Front Pediatr. 2017;5:280. [Crossref]  [PubMed]  [PMC]
  18. Gonen I, Babayigit A, Bornaun H, Yasa B, Memur S, Semerci SY, et al. SIMPLE: A novel scoring system for predicting hemodynamically significant patent ductus arteriosus without echocardiographic evaluation in extremely low birth weight infants. Front Pediatr. 2021;9:649515. [Crossref]  [PubMed]  [PMC]
  19. El-Khuffash A, James AT, Corcoran JD, Dicker P, Franklin O, Elsayed YN, et al. A Patent Ductus Arteriosus Severity Score Predicts Chronic Lung Disease or Death before Discharge. J Pediatr. 2015;167:1354-61. [Crossref]  [PubMed]
  20. Fink D, El-Khuffash A, McNamara PJ, Nitzan I, Hammerman C. Tale of Two Patent Ductus Arteriosus Severity Scores: Similarities and Differences. Am J Perinatol. 2018;35:55-8. [Crossref]  [PubMed]
  21. Giesinger RE, Hobson AA, Bischoff AR, Klein JM, McNamara PJ. Impact of early screening echocardiography and targeted PDA treatment on neonatal outcomes in "22-23" week and "24-26" infants. Semin Perinatol. 2023;47:151721. [Crossref]  [PubMed]
  22. Patel M, Gopalakrishnan M, Sundararajan S. Impact of Delayed Cord Clamping on Red Blood Cell Transfusion and Related Outcomes in Very Low Birth Weight Infants. Am J Perinatol. 2023. [Crossref]  [PubMed]
  23. Bell EF, Acarregui MJ. Restricted versus liberal water intake for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2014;2014:CD000503. [Crossref]
  24. Mitra S, Florez ID, Tamayo ME, Mbuagbaw L, Vanniyasingam T, Veroniki AA, et al. Association of Placebo, Indomethacin, Ibuprofen, and Acetaminophen With Closure of Hemodynamically Significant Patent Ductus Arteriosus in Preterm Infants: A Systematic Review and Meta-analysis. JAMA. 2018;319:1221-38. [Crossref]  [PubMed]  [PMC]
  25. Roze JC, Cambonie G, Le Thuaut A, Debillon T, Ligi I, Gascoin G, et al. Effect of Early Targeted Treatment of Ductus Arteriosus with Ibuprofen on Survival Without Cerebral Palsy at 2 Years in Infants with Extreme Prematurity: A Randomized Clinical Trial. J Pediatr. 2021;233:33-42. [Crossref]  [PubMed]
  26. Ohlsson A, Walia R, Shah SS. Ibuprofen for the treatment of patent ductus arteriosus in preterm or low birth weight (or both) infants. Cochrane Database Syst Rev. 2020;2:CD003481. [Crossref]  [PubMed]
  27. Jasani B, Mitra S, Shah PS. Paracetamol (acetaminophen) for patent ductus arteriosus in preterm or low birth weight infants. Cochrane Database Syst Rev. 2022;12:CD010061. [Crossref]  [PubMed]
  28. Bitar E, Hyderi A, Campbell SM, Kumar M. Acetaminophen versus indomethacin for patent ductus arteriosus management in premature infants: systematic review and meta-analysis of randomized controlled trials. Paediatr Child Health. 2023;28:291-8. [Crossref]  [PubMed]  [PMC]
  29. Hammerman C, Bin-Nun A, Abdaljalil H, Nitzan I, Kasirer Y, Abu-Omar R, et al. Dual Therapy vs. Monotherapy for the Patent Ductus Arteriosus: A Systematic Review. Pediatr Cardiol. 2022;43:935-42. [Crossref]  [PubMed]
  30. Yurttutan S, Bozkaya A, Hudayioglu F, Oncel MY. The effect of combined therapy for treatment of monotherapy-resistant PDA in preterm infants. J Matern Fetal Neonatal Med. 2019;32:3662-5. [Crossref]  [PubMed]  [PMC]
  31. Oncel MY, Erdeve O. Oral medications regarding their safety and efficacy in the management of patent ductus arteriosus. World J Clin Pediatr. 2016;5:75. [Crossref]  [PubMed]  [PMC]
  32. Mitra S, de Boode WP, Weisz DE, Shah PS. Interventions for patent ductus arteriosus (PDA) in preterm infants: an overview of Cochrane Systematic Reviews. Cochrane Database Syst Rev. 2023;4:CD013588. [Crossref]  [PubMed]  [PMC]
  33. Clyman RI, Kaempf J, Liebowitz M, Erdeve O, Bulbul A, Håkansson S, et al. Prolonged tracheal intubation and the association between patent ductus arteriosus and bronchopulmonary dysplasia: a secondary analysis of the PDA-TOLERATE trial. J Pediatr. 2021;229:283-8. [Crossref]  [PubMed]  [PMC]
  34. Frid I, Agren J, Kjellberg M, Normann E, Sindelar R. Critically ill neonates displayed stable vital parameters and reduced metabolic acidosis during neonatal emergency airborne transport in Sweden. Acta Paediatr. 2018;107:1357-61. [Crossref]  [PubMed]
  35. Kumar Sinha S and Neogi S. Bedside neonatal intensive care unit surgery- myth or reality! J Neonatal Surg 2013; 2: 20. 20130401. [Crossref]
  36. Rodríguez Ogando A, Planelles Asensio I, de la Blanca ARS, Ballesteros Tejerizo F, Sánchez Luna M, Gil Jaurena J, et al. Surgical ligation versus percutaneous closure of patent ductus arteriosus in very low-weight preterm infants: which are the real benefits of the percutaneous approach? Pediatr Cardiol. 2018;39:398-410. [Crossref]  [PubMed]
  37. Fraisse A, Bautista-Rodriguez C, Burmester M, Lane M, Singh Y. Transcatheter Closure of Patent Ductus Arteriosus in Infants With Weight Under 1,500 Grams. Front Pediatr. 2020;8:558256. [Crossref]  [PubMed]  [PMC]
  38. Sathanandam S, Balduf K, Chilakala S, Washington K, Allen K, Knott-Craig C, et al. Role of Transcatheter patent ductus arteriosus closure in extremely low birth weight infants. Catheter Cardiovasc Interv. 2019;93:89-96. [Crossref]  [PubMed]
  39. Lee LK, Woodfin MY, Vadi MG, Grogan TR, Ross PJ, Applegate RL 2nd,et al. A comparison of postoperative outcomes with PDA ligation in the OR versus the NICU: a retrospective cohort study on the risks of transport. BMC Anesthesiol. 2018;18:199. [Crossref]  [PubMed]  [PMC]
  40. Okulu E, Erdeve O, Arslan Z, Demirel N, Kaya H, Gokce IK, et al. An observational, prospective, multicenter, registry-based cohort study comparing conservative and medical management for patent ductus arteriosus. Front Pediatr. 2020;8:434. [Crossref]  [PubMed]  [PMC]
  41. Cambonie G, Clyman RI, Rozé JC. Management of persistent ductus arteriosus in very premature neonates. Results of the French TRIOCAPI trial, perspectives for clinicians, and subsequent studies on this topic. Arch Pediatr. 2021;28(7):501-3. [Crossref]  [PubMed]